Abstract
Building upon an earlier critique of the Food and Drug Adminstration (FDA) granting of a humanitarian device exemption for deep brain stimulation in treatment-resistant obsessive compulsive disorder, this article considers how we regulate and finance DBS. It suggests that these devices are mosaic in nature: both potentially therapeutic and probative and that their dual roles need to be appreciated to maximize their therapeutic and investigational potential.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4-8 |
| Number of pages | 5 |
| Journal | AJOB Neuroscience |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2012 |
Keywords
- bioethics
- brain
- deep brain stimulation
- minimal consciousness
- neuromodulation
- neuroprosthesis
ASJC Scopus subject areas
- General Neuroscience